-
公开(公告)号：US20050101602A1
公开(公告)日：2005-05-12
申请号：US10942035
申请日：2004-09-16
申请人： Anwer Basha , William Bunnelle , Michael Dart , Megan Gallagher , Jianguo Ji , Tao Li , Jennifer Pace , Keith Ryther , Karin Tietje , Kathleen Mortell , Diana Nersesian , Michael Schrimpf
发明人： Anwer Basha , William Bunnelle , Michael Dart , Megan Gallagher , Jianguo Ji , Tao Li , Jennifer Pace , Keith Ryther , Karin Tietje , Kathleen Mortell , Diana Nersesian , Michael Schrimpf
IPC分类号： A61K31/4178 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/53 , C07D43/14
CPC分类号： A61K31/501 , A61K31/4178 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/53
摘要： Compounds of formula (I) Z-Ar1—Ar2 (I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译： 式（I）化合物<？in-line-formula description =“In-line Formulas”end =“lead”？> Z-Ar 1 -Ar 2 I）<？in-line-formula description =“In-line Formulas”end =“tail”？>其中Z是二氮杂双环胺，Ar 1是5或6元芳环 和Ar 2 2选自未取代或取代的5或6元杂芳基环; 未取代或取代的双环杂芳基环; 3,4-（亚甲二氧基）苯基; 咔唑基; 四氢咔唑基; 萘基; 和苯基; 其中苯基在间位或对位被0,1,2或3个取代基取代。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了包含式（I）化合物和使用这些化合物和组合物的方法的药物组合物。
-
公开(公告)号：US20050245531A1
公开(公告)日：2005-11-03
申请号：US11153762
申请日：2005-06-15
申请人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schrimpf , Diana Nersesian , Liping Pan , William Bunnelle
发明人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schrimpf , Diana Nersesian , Liping Pan , William Bunnelle
IPC分类号： C07D453/02 , C07D453/04 , A61K31/501 , A61K31/506
CPC分类号： C07D453/02
摘要： Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译： 其中n为0,1或2的式（I）化合物; A是N或N + O，-O-; X是O，S，-NH-和-N-烷基 - ; Ar 1是6元芳环; 并且Ar 2是稠合的双环杂环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式（I）化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号：US20070060588A1
公开(公告)日：2007-03-15
申请号：US11450800
申请日：2006-06-09
申请人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schrimpf , Diana Nersesian , Liping Pan , William Bunnelle
发明人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schrimpf , Diana Nersesian , Liping Pan , William Bunnelle
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4745 , C07D453/02 , C07D471/02
CPC分类号： C07D453/02
摘要： Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O−; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译： 其中n为0,1或2的式（I）化合物; A是N或N + O - - O - X是O，S，-NH-和-N-烷基 - ; Ar 1是6元芳环; 并且Ar 2是稠合的双环杂环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式（I）化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号：US20050137204A1
公开(公告)日：2005-06-23
申请号：US11015236
申请日：2004-12-17
申请人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schimpf , Diana Nersesian , Liping Pan
发明人： Jianguo Ji , Tao Li , Kathleen Mortell , Michael Schimpf , Diana Nersesian , Liping Pan
IPC分类号： C07D453/02 , A61K31/506 , A61K31/4745 , A61K31/497 , A61K31/501
CPC分类号： C07D453/02
摘要： Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O−; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译： 其中n为0,1或2的式（I）化合物; A是N或N + O - - O - X是O，S，-NH-和-N-烷基 - ; Ar 1是6元芳环; 并且Ar 2是稠合的双环杂环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式（I）化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号：US20070072892A1
公开(公告)日：2007-03-29
申请号：US11517064
申请日：2006-09-07
IPC分类号： A61K31/4745 , C07D221/22
CPC分类号： C07D487/04
摘要： The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.
摘要翻译： 本发明涉及胺取代的氮杂 - 金刚烷衍生物，包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。 还描述了可用于评估对α7烟碱乙酰胆碱受体的结合亲和力的放射性标记化合物。
-
公开(公告)号：US20080234308A2
公开(公告)日：2008-09-25
申请号：US11517064
申请日：2006-09-07
IPC分类号： A61K31/4745 , C07D221/22
CPC分类号： C07D487/04
摘要： The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.
摘要翻译： 本发明涉及胺取代的氮杂 - 金刚烷衍生物，包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。 还描述了可用于评估对α7烟碱乙酰胆碱受体的结合亲和力的放射性标记化合物。
-
公开(公告)号：US20050272736A1
公开(公告)日：2005-12-08
申请号：US11123324
申请日：2005-05-06
申请人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
发明人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
IPC分类号： A61K31/4709 , A61K31/4745 , A61K31/498 , A61K31/519 , C07D401/06 , C07D405/04 , C07D417/04 , C07D417/14 , C07D471/02 , C07D471/04 , C07D487/02 , C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
CPC分类号： C07D471/04 , C07D401/06 , C07D405/04 , C07D417/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
摘要： Compounds of formula (I) wherein R1 or R2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R1, R2, R3, R3a, R3b, R4, R5, L, X, X′, Y, Y′, Z, and Z′ are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译： 其中R 1或R 2的式（I）化合物是三环或双环，其各自含有至少两个杂原子，R 1，R 2， R 2，R 2，R 3，R 3a，R 3b，R 4， R 3，R 5，L，X，X'，Y，Y'，Z和Z'如本文所定义，可用于治疗组胺3阻止或改善的病症或病症 受体配体。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。
-
8.发明申请Bicyclic-substituted amines having cyclic-substituted monocyclic substituents 审中-公开具有环取代的单环取代基的双环取代的胺公开(公告)号：US20050256118A1
公开(公告)日：2005-11-17
申请号：US10843742
申请日：2004-05-12
申请人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
发明人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
IPC分类号： A61K31/4709 , C07D215/12 , C07D401/04 , C07D401/08 , C07D401/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , A61K31/5377 , A61K31/497 , C07D49/14
CPC分类号： C07D215/12 , C07D401/04 , C07D401/08 , C07D401/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译： 其中R 1或R 2的式（I）化合物是由L 2直接连接或连接的芳族或非芳族环， X，X'，Y，Y'，Z，Z'，R 1，R 3， R 3，R 3，R 3a，R 3b，R 4，R 3， 5，L，L 2和L 3 3如本文所定义，可用于治疗组胺3受体配体预防或改善的病症或病症 。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。
-
公开(公告)号：US20060194798A1
公开(公告)日：2006-08-31
申请号：US11418699
申请日：2006-05-05
申请人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Padam Sharma , Youssef Bennani , Michael Curtis
发明人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Padam Sharma , Youssef Bennani , Michael Curtis
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/4709 , A61K31/427 , C07D417/02 , C07D403/02
CPC分类号： C07D207/14 , C07D207/08 , C07D207/12 , C07D207/20 , C07D213/30 , C07D213/38 , C07D213/61 , C07D213/64 , C07D213/85 , C07D215/12 , C07D215/14 , C07D215/20 , C07D217/14 , C07D237/12 , C07D237/14 , C07D237/28 , C07D239/26 , C07D239/28 , C07D239/42 , C07D239/52 , C07D241/12 , C07D241/42 , C07D263/32 , C07D277/28 , C07D295/073 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/135 , C07D295/155 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/10 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D471/04
摘要： Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译： 式（I）化合物可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。
-
公开(公告)号：US20050272728A1
公开(公告)日：2005-12-08
申请号：US11123620
申请日：2005-05-06
申请人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
发明人： Robert Altenbach , Lawrence Black , Sou-Jen Chang , Marlon Cowart , Ramin Faghih , Gregory Gfesser , Yi-Yin Ku , Huaqing Liu , Kirill Lukin , Diana Nersesian , Yu-ming Pu , Michael Curtis
IPC分类号： A61K31/4709 , A61K31/5377 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC分类号： C07D409/14 , C07D401/14 , C07D413/14 , C07D417/14
摘要： Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.057 秒)
